Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES (ABT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Former Abbott Drug Unit Recalls Synthroid Again

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2013 | 09:36pm CEST

Abbott Laboratories' (>> Abbott Laboratories) former pharmaceutical unit, now spun off as AbbVie Inc. (>> AbbVie Inc), recently recalled more than 28,520 bottles of the thyroid-hormone replacement therapy Synthroid over a dose mix-up, marking the second recall of the drug in six months.

One lot of 150-microgram Synthroid tablets was recalled because one bottle was found to contain lower-dose, 75-microgram tablets, AbbVie spokesman Gregory Miley said Friday. The voluntary recall was initiated in early December as a precaution, he said.

The cause was a "manufacturing line clearance error," he said, and AbbVie has taken corrective action. The company isn't aware of any increase in patient complaints or adverse events associated with the label error.

AbbVie was spun off to Abbott shareholders as an independent company at the start of January. AbbVie assumed Synthroid's U.S. marketing rights, though Abbott Labs continues to market the drug outside the U.S.

In July, Abbott recalled three lots of Synthroid because some bottles had defects that could affect the stability of the tablets at the end of shelf life. More than 136,500 bottles of Synthroid were subject to that recall, though Abbott said a majority of them remained under Abbott's control and weren't shipped out.

Both Synthroid recalls were classified by the FDA as Class II, which is typically applied in situations where a product might cause a temporary health problem or pose only a slight threat of a serious health problem.

Synthroid is a synthetic thyroid hormone used by people with hypothyroidism, in which the thyroid gland doesn't produce enough natural thyroid hormone.

Abbott reported $461 million of global Synthroid sales for the first nine months of 2012.

AbbVie shares were recently down a penny at $33.61.

Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, AbbVie Inc
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES -0.22% 62.37 Delayed Quote.8.36%
ABBVIE -2.00% 101.08 Delayed Quote.6.65%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
05/25ABBOTT LABORATORIES : Trademark Application for "PHOSPHAGEN" Filed by Abbott Lab..
AQ
05/25ABBOTT LABORATORIES : Trademark Application for "COMMITTED TO THE C.A.S.E." File..
AQ
05/24ABBOTT LABORATORIES : Investigational tendyne device for mitral valve replacemen..
AQ
05/24ABBOTT LABORATORIES : - newest generation of leading heart stent is now approved..
AQ
05/24ABBOTT LABORATORIES : Real-World Study Results Support Use of Abbott's AMPLATZER..
PU
05/23ABBOTT LABORATORIES : Newest Generation of Leading Heart Stent is Now Approved i..
PR
05/23ABBOTT : 's Investigational Tendyne™ Device for Mitral Valve Replacement D..
PR
05/23ABBOTT LABORATORIES : $96,439 Federal Contract Awarded to Abbott Laboratories
AQ
05/22ABBOTT LABORATORIES : Treatment with Abbott's Portico™ Transcatheter Aorti..
PU
05/22ABBOTT LABORATORIES : Five-Year Study Data Confirm Positive Outcomes for Patient..
PR
More news
News from SeekingAlpha
05/23Abbott's Tendyne mitral valve shows positive effect in global study 
05/22Abbott's stent guide improved outcomes in long-term study 
05/18MeiraGTx Aims For $86 Million U.S. IPO 
05/16THE 30+1 PORTFOLIO : An Average Investor's Reasoning For Buying A Stock 
05/03My Dividend Growth Portfolio - 42 Holdings, 4 Buys 
Financials ($)
Sales 2018 30 950 M
EBIT 2018 6 458 M
Net income 2018 2 536 M
Debt 2018 15 152 M
Yield 2018 1,79%
P/E ratio 2018 47,96
P/E ratio 2019 34,03
EV / Sales 2018 4,03x
EV / Sales 2019 3,72x
Capitalization 110 B
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 68,5 $
Spread / Average Target 9,6%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian Bernard Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Glenn Fletcher Tilton Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES8.36%109 592
JOHNSON & JOHNSON-11.45%327 893
PFIZER-1.16%209 941
NOVARTIS-6.94%193 872
ROCHE HOLDING LTD.-9.17%190 404
MERCK AND COMPANY5.08%159 078